HC Wainwright Weighs in on Marinus Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities research analysts at HC Wainwright decreased their Q1 2024 earnings per share estimates for Marinus Pharmaceuticals in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings per share of ($0.70) for the quarter, down from their previous estimate of ($0.69). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.52) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($2.15) EPS, Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at $0.91 EPS and FY2028 earnings at $2.86 EPS.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The firm had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $7.78 million. During the same period in the prior year, the company earned ($0.76) EPS.

A number of other brokerages have also issued reports on MRNS. Royal Bank of Canada reissued a “sector perform” rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. Oppenheimer reaffirmed a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. StockNews.com lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Truist Financial reduced their target price on Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Finally, Robert W. Baird reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, April 16th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Marinus Pharmaceuticals has an average rating of “Hold” and a consensus target price of $13.79.

Marinus Pharmaceuticals Stock Down 8.9 %

Shares of Marinus Pharmaceuticals stock opened at $1.43 on Thursday. The company’s 50 day moving average price is $6.18 and its 200-day moving average price is $7.84. Marinus Pharmaceuticals has a 52-week low of $1.11 and a 52-week high of $11.26. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07. The stock has a market capitalization of $78.55 million, a price-to-earnings ratio of -0.54 and a beta of 1.14.

Institutional Trading of Marinus Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Jennison Associates LLC lifted its position in Marinus Pharmaceuticals by 58.4% during the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after acquiring an additional 1,089,913 shares during the period. Victory Capital Management Inc. boosted its position in shares of Marinus Pharmaceuticals by 61.2% in the 3rd quarter. Victory Capital Management Inc. now owns 94,550 shares of the biopharmaceutical company’s stock worth $761,000 after purchasing an additional 35,890 shares in the last quarter. Alpha DNA Investment Management LLC purchased a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth approximately $621,000. Sherbrooke Park Advisers LLC bought a new position in Marinus Pharmaceuticals during the 3rd quarter valued at approximately $141,000. Finally, Schonfeld Strategic Advisors LLC raised its stake in Marinus Pharmaceuticals by 69.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock valued at $2,040,000 after buying an additional 103,935 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.